Skip to main content
    • Aa
    • Aa

Contingent valuation: what needs to be done?

  • Richard D. Smith (a1) and Tracey H. Sach (a2)

Contingent valuation (CV) has been argued to have theoretical advantages over other approaches for benefit valuation used by health economists. Yet, in reality, the technique appears not to have realised these advantages when applied to health-care issues, such that its influence in decision-making at national levels has been non-existent within the health sector. This is not a result of a lack of methodological work in the area, which has continued to flourish. Rather, it is a result of such activities being undertaken in a rather uncoordinated and unsystematic fashion, leading CV to be akin to a ‘ship without a sail’. This paper utilises a systematic review of the CV literature in health to illustrate some important points concerning the conduct of CV studies, before providing a comment on what the remaining policy and research priorities are for the technique, and proposing a guideline for such studies. It is hoped that this will initiate some wider and rigorous debate on the future of the CV technique in order to make it seaworthy, give it direction and provide the right momentum.

Corresponding author
Correspondence to: Richard D. Smith, Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

J. P. Acton (1976), ‘Measuring the monetary value of lifesaving programs’, Law and Contemporary Problems, 40: 4672.

I. Bateman , R. T. Carson , B. Day , W. M. Hanemann , N. Hanley , T. Hett , A. Jones , G. Loomes , S. Mourato , E. Ozdemiroglu , D. W. Pearce , R. Sugden J. Swanson (2002), Economic Valuation with Stated Preferences Techniques. A Manual, Cheltenham: Edward Elgar.

H. Bleichrodt J. Quiggin (1999), ‘Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost–benefit analysis?’, Journal of Health Economics, 18(6): 681708.

M. J. Buxton (2005), ‘How much are health-care systems prepared to pay to produce a QALY?’, European Journal of Health Economics, 6: 285287.

M. M. Byrne , K. O’malley M. E. Suarez-Almazor (2005), ‘Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis’, Medical Decision Making, 25: 655666.

R. Cookson (2003), ‘Willingness to pay methods in health care: a sceptical view’, Health Economics, 12: 891894.

J. Covey R. D. Smith (2006), ‘How common is the “prominence effect”? Additional evidence to Whynes et al., Health Economics, 15: 205210.

N. Devlin D. Parkin (2004), ‘Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis, Health Economics, 13: 437452.

A. Diener , B. O’Brien A. Gafni (1998), ‘Health care contingent valuation studies: a review and classification of the literature’, Health Economics, 7: 313326.

P. Dolan R. Edlin (2002), ‘Is it really possible to build a bridge between cost–benefit analysis and cost-effectiveness analysis?’, Journal of Health Economics, 21: 827843.

H. G. Eichler , S. X. Kong , W. C. Gert , P. Mavros B. Jonsson (2004), ‘Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?’, Value in Health, 7: 518528.

D. M. Franica , D. S. Pathakb A. Gafni (2005), ‘Quality-adjusted life years was a poor predictor of women’s willingness to pay in acute and chronic conditions: results of a survey’, Journal of Clinical Epidemiology, 58: 291303.

E. J. Frew , D. K. Whynes J. L. Wolstenholme (2003), ‘Eliciting willingness to pay: comparing closed-ended with open-ended and payment scale formats’, Medical Decision Making, 23: 150159.

A. Gafni S. Birch (2006), ‘Incremental cost-effectiveness ratios (ICERs): the silence of the lambda’, Social Science and Medicine, 62: 20912100.

A. M. Garber C. E. Phelps (1997), ‘Economic foundations of cost-effectiveness analysis’, Journal of Health Economics, 16(1): 131.

B. George , A. Harris A. Mitchell (2001), ‘Cost-effectiveness analysis and the consistency of decision-making. Evidence from pharmaceutical reimbursement in Australia (1991–1996)’, PharmacoEconomics, 19: 11031109.

D. Gyrd-Hansen (2003), ‘Willingness to pay for a QALY’, Health Economics, 12: 10491060.

N. Hanley , M. Ryan R. Wright (2003), ‘Estimating the monetary value of health care: lessons from environmental economics’, Health Economics, 12: 316.

R. A. Hirth , M. E. Chernew , E. Miller , A. M. Fendrick W. G. Weissert (2000), ‘Willingness to pay for a quality-adjusted life year: in search of a standard’, Medical Decision Making, 20: 332342.

M. Johannesson (1995), ‘The relationship between cost-effectiveness analysis and cost–benefit analysis’, Social Science and Medicine, 41: 483489.

F. R. Johnson , E. E. Fries H. S. Banzhaf (1997), ‘Valuing morbidity: an integration of the willingness to pay and health status index literature’, Journal of Health Economics, 16: 641665.

J. T. King , J. Tsevat , J. R. Lave M. S. Roberts (2005), ‘Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation’, Medical Decision Making, 25: 667677.

T. Klose (1999), ‘The contingent valuation method in health care’, Health Policy, 47: 97123.

J. A. Olsen R. D. Smith (2001), ‘Theory versus practice: A review of “willingness-to-pay” in health and health care’, Health Economics, 10: 3952.

M. Rawlins A. Culyer (2004), ‘National Institute for Clinical Excellence and its value judgements’, British Medical Journal, 329: 224227.

J. Richardson R. D. Smith (2004), ‘Calculating society’s willingness-to-pay for a QALY: key questions for discussion’, Applied Health Economics and Health Policy, 3(3): 125126.

T. Sach , R. D. Smith D. Whynes (2007), ‘A “league table” of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?’, PharmacoEconomics, 25: 107127.

R. D. Smith (2000), ‘The discrete choice willingness-to-pay question format in Health Economics: should we adopt environmental guidelines?’, Medical Decision Making, 20(2): 194206.

R. D. Smith (2001), ‘The relative sensitivity of willingness-to-pay and time-trade-off to changes in health status: an empirical investigation’, Health Economics, 10: 487497.

R. D. Smith (2003), ‘Construction of the contingent valuation market in health care: a critical assessment’, Health Economics, 12: 609628.

R. D. Smith (2004), ‘The reliability of willingness to pay for changes in health status’, Applied Health Economics and Health Policy, 3(1): 3538.

R. D. Smith (2005), ‘Sensitivity to scale in contingent valuation: the importance of the budget constraint’, Journal of Health Economics, 24: 515529.

R. D. Smith (2006), ‘Its not just what you do, its the way that you do it: the effect of different payment card formats and survey administration on willingness to pay for health gain’, Health Economics, 15: 281293.

R. D. Smith J. Richardson (2005), ‘Can we estimate the “social” value of a QALY? Four core issues to resolve’, Health Policy, 74: 7784.

R. D. Smith (2007), ‘Use, option and externality values: are contingent valuation studies in health care mis-specified?’, Health Economics, 16: 861869.

R. D. Smith (2007a), ‘The relationship between reliability and size of willingness to pay values: a qualitative insight’, Health Economics, 16: 211216.

R. D. Smith (2007b), ‘The role of “reference goods” in contingent valuation: should we help respondents to “construct” their willingness to pay?’, Health Economics, 16: 13191332.

R. D. Smith (2008), ‘Contingent valuation in health care: does it matter how the “good” is described?’, Health Economics, 17: 607617.

G. Van Houtven , J. Powers , A. Jessup J.-C. Yang (2006), ‘Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP?’, Health Economics, 15: 775795.

D. K. Whynes , E. J. Frew J. L. Wolstenholme (2003), ‘A comparison of two methods for eliciting contingent valuations of colorectal cancer screening’, Journal of Health Economics, 22: 555574.

D. Whynes , E. Frew , Z. Philips , J. Covey R. D. Smith (2007), ‘The “prominence effect” on contingent valuation’, Journal of Economic Psychology, 28: 462476.

R. Y. T. Yeung R. D. Smith (2006), ‘Can we use contingent valuation to assess the private demand for childhood immunization in developing countries? A systematic review of the literature’, Applied Health Economics and Health Policy, 4: 165173.

R. Y. T. Yeung , R. D. Smith S. M. McGhee (2003), ‘Willingness to pay and size of health benefit: an integrated model to test for “sensitivity to scale” ’, Health Economics, 12(9): 791796.

R. Y. T. Yeung , R. D. Smith , L. M. Ho , J. Johnston G. Leung (2006), ‘Empirical implications of response acquiescence in discrete-choice contingent valuation’, Health Economics, 15: 10771089.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Health Economics, Policy and Law
  • ISSN: 1744-1331
  • EISSN: 1744-134X
  • URL: /core/journals/health-economics-policy-and-law
Please enter your name
Please enter a valid email address
Who would you like to send this to? *